Kidney Week

Abstract: INFO19-FR

The Cure Glomerulonephropathy Network

Session Information

• Informational Posters - 2
  October 23, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• No subcategory defined

Authors

• Helmuth, Margaret, University of Michigan Michigan Medicine, Ann Arbor, Michigan, United States

Margaret Helmuth, MA

• Smith, Abigail R., Northwestern University, Evanston, Illinois, United States

Abigail R. Smith, PhD

• Banker, Margaret, Northwestern University, Evanston, Illinois, United States

Margaret Banker, PhD

• Chen, Dhruti P., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Dhruti P. Chen, MD, FASN

• Fischman, Clara, Penn Medicine, Philadelphia, Pennsylvania, United States

Clara Fischman, MD, MS

• Freeman, Natasha, Columbia University, New York, New York, United States

Natasha Freeman, MD, MS

• Kenan, Anna, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Anna Kenan, MD

• Konda, Raghunandan, The University of Alabama at Birmingham, Birmingham, Alabama, United States

Raghunandan Konda, MD, MBBS

• Kowalczyk, Sonya R., The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Sonya R. Kowalczyk, MD

• Reynolds, Monica Lona, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Monica Lona Reynolds, MD, MS, FASN

• Shen, Carol L., Northwell Health, New Hyde Park, New York, United States

Carol L. Shen, MD

• Wang, Qiyu, Brigham and Women's Hospital, Boston, Massachusetts, United States

Qiyu Wang, MD

• Wyatt, Nicole Elizabeth, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Nicole Elizabeth Wyatt, DO

• Mariani, Laura H., University of Michigan Michigan Medicine, Ann Arbor, Michigan, United States

Laura H. Mariani, MD, MS, FASN

Description

CureGN is a multi-center, prospective observational cohort study of glomerular disease funded by the NIH-NIDDK. CureGN has enrolled 2,999 participants with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy/vasculitis from 72 sites internationally since Dec 2014.
Pediatric and adult patients who underwent a kidney biopsy within 5 years of enrollment are eligible to participate. Exclusion criteria include kidney failure at enrollment, diabetes at biopsy, and glomerular disease attributed to a secondary cause. Sociodemographic, clinical, pathologic, and patient-reported data are collected and enriched by a diverse biorepository and Digital Pathology Repository (DPR). Renal and non-renal outcomes are assessed. Participant characteristics with a median 6.3-year follow-up are shown.
CureGN supports multidimensional translational research by integrating clinical, pathology, and outcome data with longitudinal DNA, RNA, blood, and urine specimens. To date, whole genome sequencing and RNA sequencing have been completed for 2,006 and 2,125 patients, respectively. The DPR provides annotated images and quantitative scoring data from kidney biopsies, and currently stores images from 1,988 patient biopsies, of which 1,202 are scored. An online data-sharing platform (tranSMART) supports hypothesis generation.
The study objectives support identifying mechanistically distinct subgroups, discovering/validating biomarkers, delineating disease-specific treatment targets, and informing future therapeutic trials to advance the diagnosis, care, and outcomes of glomerular diseases. Patient input is integrated via a patient advisory panel. The Career Development Group provides peer mentoring for young investigators interested in glomerular disease. The consortium is open to ancillary study proposals from network and extramural investigators.

Funding

• Funding for the CureGN consortium is provided by U24DK100845, U01DK100846, U01DK100876, U01DK100866, and U01DK100867 from the NIDDK. Patient Recruitment is supported by NephCure. The Nephrotic Syndrome Study Network (NEPTUNE) is part of the Rare Diseases Clinical Research Network (RDCRN) and funded by the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (U54DK083912).